SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-20-046926
Filing Date
2020-04-15
Accepted
2020-04-15 16:30:15
Documents
6
Period of Report
2020-06-07
Effectiveness Date
2020-04-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2015338-1_def14a.htm DEF 14A 700539
2 GRAPHIC lg_protalix.jpg GRAPHIC 37587
3 GRAPHIC sg_drorbashan.jpg GRAPHIC 126889
4 GRAPHIC sg_eyalrubin-bw.jpg GRAPHIC 45860
5 GRAPHIC tm2015338d1-pc1.jpg GRAPHIC 471316
6 GRAPHIC tm2015338d1-pc2.jpg GRAPHIC 693696
  Complete submission text file 0001104659-20-046926.txt   2591871
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 20794035
SIC: 2836 Biological Products, (No Diagnostic Substances)